The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Christian H Geisler; Arne Kolstad; Anna Laurell; Riikka Räty; Mats Jerkeman; Mikael Eriksson; Marie Nordström; Eva Kimby; Anne Marie Boesen; Herman Nilsson-Ehle; Outi Kuittinen; Grete F Lauritzsen; Elisabeth Ralfkiaer; Mats Ehinger; Christer Sundström; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen; Nordic Lymphoma Group

doi:10.1182/blood-2009-08-236570

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Christian H Geisler, Arne Kolstad, Anna Laurell, Riikka Räty, Mats Jerkeman, Mikael Eriksson, Marie Nordström, Eva Kimby, Anne Marie Boesen, Herman Nilsson-Ehle, Outi Kuittinen, Grete F Lauritzsen, Elisabeth Ralfkiaer, Mats Ehinger, Christer Sundström, Jan Delabie, Marja-Liisa Karjalainen-Lindsberg, Peter Brown, Erkki Elonen, Nordic Lymphoma Group

132 Citations (Scopus)

Abstract

Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCLbetter than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPI_B (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPIB is feasible. This trial was registered at www.isrctn.org as #ISRCTN 87866680.

Original language	English
Journal	Blood
Volume	115
Issue number	8
Pages (from-to)	1530-3
Number of pages	4
ISSN	0006-4971
DOIs	https://doi.org/10.1182/blood-2009-08-236570
Publication status	Published - 25 Feb 2010

Access to Document

10.1182/blood-2009-08-236570

http://www.bloodjournal.org/content/bloodjournal/115/8/1530.full.pdf

Fingerprint

Dive into the research topics of 'The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)'. Together they form a unique fingerprint.

Cite this

Geisler, C. H., Kolstad, A., Laurell, A., Räty, R., Jerkeman, M., Eriksson, M., Nordström, M., Kimby, E., Boesen, A. M., Nilsson-Ehle, H., Kuittinen, O., Lauritzsen, G. F., Ralfkiaer, E., Ehinger, M., Sundström, C., Delabie, J., Karjalainen-Lindsberg, M.-L., Brown, P., Elonen, E., & Nordic Lymphoma Group (2010). The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood, 115(8), 1530-3. https://doi.org/10.1182/blood-2009-08-236570

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). / Geisler, Christian H; Kolstad, Arne; Laurell, Anna et al.
In: Blood, Vol. 115, No. 8, 25.02.2010, p. 1530-3.

Research output: Contribution to journal › Journal article › Research › peer-review

Geisler, CH, Kolstad, A, Laurell, A, Räty, R, Jerkeman, M, Eriksson, M, Nordström, M, Kimby, E, Boesen, AM, Nilsson-Ehle, H, Kuittinen, O, Lauritzsen, GF, Ralfkiaer, E, Ehinger, M, Sundström, C, Delabie, J, Karjalainen-Lindsberg, M-L, Brown, P, Elonen, E & Nordic Lymphoma Group 2010, 'The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)', Blood, vol. 115, no. 8, pp. 1530-3. https://doi.org/10.1182/blood-2009-08-236570

Geisler CH, Kolstad A, Laurell A, Räty R, Jerkeman M, Eriksson M et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010 Feb 25;115(8):1530-3. doi: 10.1182/blood-2009-08-236570

@article{ebf52652b94e416c947db245431fcad6,

title = "The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)",

abstract = "Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCLbetter than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPIB (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPIB is feasible. This trial was registered at www.isrctn.org as #ISRCTN 87866680.",

author = "Geisler, {Christian H} and Arne Kolstad and Anna Laurell and Riikka R{\"a}ty and Mats Jerkeman and Mikael Eriksson and Marie Nordstr{\"o}m and Eva Kimby and Boesen, {Anne Marie} and Herman Nilsson-Ehle and Outi Kuittinen and Lauritzsen, {Grete F} and Elisabeth Ralfkiaer and Mats Ehinger and Christer Sundstr{\"o}m and Jan Delabie and Marja-Liisa Karjalainen-Lindsberg and Peter Brown and Erkki Elonen and Ralfki{\ae}r, {Elisabeth Methner}",

year = "2010",

month = feb,

day = "25",

doi = "10.1182/blood-2009-08-236570",

language = "English",

volume = "115",

pages = "1530--3",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "8",

}

TY - JOUR

T1 - The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

AU - Geisler, Christian H

AU - Kolstad, Arne

AU - Laurell, Anna

AU - Räty, Riikka

AU - Jerkeman, Mats

AU - Eriksson, Mikael

AU - Nordström, Marie

AU - Kimby, Eva

AU - Boesen, Anne Marie

AU - Nilsson-Ehle, Herman

AU - Kuittinen, Outi

AU - Lauritzsen, Grete F

AU - Ralfkiaer, Elisabeth

AU - Ehinger, Mats

AU - Sundström, Christer

AU - Delabie, Jan

AU - Karjalainen-Lindsberg, Marja-Liisa

AU - Brown, Peter

AU - Elonen, Erkki

AU - Nordic Lymphoma Group

PY - 2010/2/25

Y1 - 2010/2/25

N2 - Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCLbetter than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPIB (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPIB is feasible. This trial was registered at www.isrctn.org as #ISRCTN 87866680.

AB - Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCLbetter than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPIB (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPIB is feasible. This trial was registered at www.isrctn.org as #ISRCTN 87866680.

U2 - 10.1182/blood-2009-08-236570

DO - 10.1182/blood-2009-08-236570

M3 - Journal article

SN - 0006-4971

VL - 115

SP - 1530

EP - 1533

JO - Blood

JF - Blood

IS - 8

ER -